Acute Insomnia 

Dr Neeraj Manikath , claude.ai

Abstract

Acute insomnia, defined as difficulty initiating or maintaining sleep lasting less than three months, affects approximately 15-20% of adults annually and represents a common yet often inadequately addressed complaint in internal medicine practice. This review synthesizes current evidence on pathophysiology, clinical assessment, and management strategies, with emphasis on practical approaches for busy clinicians. Recognition and appropriate early intervention are critical, as approximately 40-50% of acute insomnia cases progress to chronic insomnia disorder if left untreated.

Introduction

Acute insomnia disorder, as defined by the International Classification of Sleep Disorders, Third Edition (ICSD-3), represents a distinct clinical entity characterized by difficulty initiating sleep, maintaining sleep, or early morning awakening, accompanied by daytime impairment, occurring at least three nights per week but lasting less than three months. While often dismissed as a minor complaint, acute insomnia significantly impacts quality of life, work productivity, and serves as a risk factor for depression, anxiety disorders, cardiovascular events, and chronic insomnia.

Pearl #1: The "3-3-3 rule" helps identify insomnia disorder: symptoms occurring ≥3 nights per week, for ≥3 months (chronic) or <3 months (acute), with ≥3 domains of daytime impairment (mood, cognition, energy, performance, safety concerns, or physical symptoms).

Epidemiology and Impact

The prevalence of acute insomnia ranges from 15-20% in the general adult population, with higher rates observed in women (1.4:1 female-to-male ratio), older adults, shift workers, and those with medical or psychiatric comorbidities. The economic burden is substantial, with estimated annual costs exceeding $100 billion in the United States when accounting for direct healthcare costs, lost productivity, and accident-related expenses.

Longitudinal studies demonstrate that untreated acute insomnia predicts the development of major depressive disorder (OR 2.0-4.0), generalized anxiety disorder (OR 2.5-3.5), and substance use disorders. Additionally, even short-term sleep disruption adversely affects glucose metabolism, blood pressure regulation, and inflammatory markers.

Pathophysiology

The pathophysiology of acute insomnia centers on the "3P model" developed by Spielman: predisposing factors (genetic vulnerability, hyperarousal tendency), precipitating factors (stressful life events, medical illness, environmental changes), and perpetuating factors (maladaptive behaviors and cognitive patterns that maintain insomnia).

Neurobiological Mechanisms

Sleep-wake regulation involves complex interactions between homeostatic sleep drive (Process S, mediated by adenosine accumulation) and circadian rhythmicity (Process C, governed by the suprachiasmatic nucleus). Acute insomnia primarily involves disruption of the descending inhibitory pathways from the ventrolateral preoptic nucleus (VLPO) to arousal centers, resulting in cortical and autonomic hyperarousal.

Neuroimaging studies reveal increased metabolic activity in the anterior cingulate cortex, prefrontal regions, and hippocampus during sleep attempts in insomnia patients, suggesting failure of normal sleep-related deactivation. Neuroendocrine dysregulation, particularly elevated evening cortisol and blunted cortisol awakening response, characterizes the acute insomnia state.

Pearl #2: Acute insomnia represents a state of "hyperarousal" across multiple domains: cognitive (racing thoughts, worry), emotional (anxiety, frustration), physiological (elevated heart rate, metabolic rate, body temperature), and cortical (increased high-frequency EEG activity).

Clinical Evaluation

History Taking

A systematic approach to history-taking is essential. The mnemonic "BEARS" (Bedtime problems, Excessive daytime sleepiness, Awakenings, Regularity and duration of sleep, Snoring) provides a useful framework, though it requires modification for adult patients.

Key elements include:

Sleep Pattern Assessment: Typical bedtime and rise time, sleep latency (time to fall asleep), number and duration of awakenings, total sleep time, sleep quality perception, and day-to-day variability. A two-week sleep diary provides invaluable objective data.

Precipitating Factors: Recent life stressors (bereavement, job loss, relationship issues, financial concerns), medical events (hospitalization, new diagnosis, pain), medications (corticosteroids, beta-agonists, stimulating antidepressants, decongestants), and environmental changes (travel, new residence, noise).

Perpetuating Behaviors: Excessive time in bed, irregular sleep-wake schedule, daytime napping, stimulant use (caffeine after 2 PM, nicotine), alcohol as a sleep aid, and bedroom activities incompatible with sleep (work, television, smartphone use).

Daytime Consequences: Mood disturbance, cognitive impairment (concentration, memory), fatigue, reduced motivation, occupational or social dysfunction, and safety concerns (driving, operating machinery).

Hack #1: Ask patients to estimate their "sleep efficiency" = (total sleep time/time in bed) × 100. Normal sleep efficiency is ≥85%. Values <85% suggest significant sleep disruption and guide therapy. This simple calculation helps patients understand their sleep problem objectively.

Physical Examination

While physical examination is rarely diagnostic for acute insomnia, it serves to identify contributing medical conditions. Focus on:

• Cardiovascular: signs of heart failure (orthopnea may mimic insomnia)
• Respiratory: evidence of obstructive sleep apnea (OSA) - obesity, crowded oropharynx (Mallampati score), hypertension
• Neurological: cognitive impairment, movement disorders, neuropathic pain
• Endocrine: thyroid enlargement or stigmata of thyroid disease
• Psychiatric: signs of depression or anxiety

Oyster #1: Always inquire about snoring, witnessed apneas, and gasping arousals. Approximately 30% of insomnia complaints actually represent undiagnosed obstructive sleep apnea or comorbid insomnia-OSA. Missed OSA diagnosis can lead to ineffective treatment and potentially harmful sedative-hypnotic use.

Differential Diagnosis

Acute insomnia must be distinguished from:

Sleep-Related Breathing Disorders: OSA typically presents with unrefreshing sleep and excessive daytime sleepiness rather than difficulty initiating sleep, though overlap exists.

Circadian Rhythm Disorders: Delayed or advanced sleep-wake phase disorder presents with inability to sleep at desired times but normal sleep when occurring at the individual's circadian preference.

Restless Legs Syndrome (RLS): Characterized by uncomfortable leg sensations and urge to move, worse with rest, relieved by movement, and following circadian pattern (worse in evening/night). Affects sleep initiation.

Periodic Limb Movement Disorder: Causes sleep fragmentation but patients are usually unaware of movements.

Adjustment Disorder with Anxiety/Depressed Mood: Insomnia may be the presenting symptom of a primary psychiatric condition.

Hack #2: Use the "RLS diagnostic tetrad" mnemonic - URGE: Uncomfortable sensations, Rest makes it worse, Gets better with movement, Evening/night predominance. All four must be present.

Management Approach

Treatment of acute insomnia emphasizes non-pharmacological interventions as first-line therapy, with judicious short-term use of medications when necessary. The goal is rapid symptom relief while preventing progression to chronic insomnia.

Non-Pharmacological Interventions

Sleep Hygiene Education: While sleep hygiene alone rarely resolves insomnia, it provides the foundation for other interventions:

• Regular sleep-wake schedule (including weekends)
• Bedroom optimization: cool (60-67°F), dark, quiet
• Limit caffeine after 2 PM, avoid alcohol within 3 hours of bedtime
• Regular exercise (not within 2-3 hours of bedtime)
• Light exposure: bright light in morning, dim light in evening
• Avoid large meals near bedtime

Brief Behavioral Therapy for Insomnia (bBTI): Adapted from cognitive-behavioral therapy for insomnia (CBT-I), bBTI can be delivered in 2-4 sessions and includes:

Stimulus Control Therapy: Re-associate bed with sleep by:

• Using bed only for sleep and sex
• Going to bed only when sleepy
• Leaving bed if unable to sleep within 20 minutes
• Consistent wake time regardless of sleep duration
• Eliminating daytime naps

Sleep Restriction Therapy: Consolidate sleep by limiting time in bed to match actual sleep time, then gradually increasing. For example, if a patient sleeps 5 hours but spends 9 hours in bed, restrict time in bed to 5.5 hours initially. This increases homeostatic sleep drive and improves sleep efficiency.

Pearl #3: Sleep restriction creates mild sleep deprivation, which therapeutically increases sleep pressure. Set a non-negotiable wake time first, then work backward to calculate bedtime. Never restrict time in bed below 5 hours for safety reasons.

Cognitive Therapy: Address maladaptive beliefs:

• Catastrophizing about lost sleep ("I'll never function tomorrow")
• Unrealistic sleep expectations ("I need 8 hours every night")
• Performance anxiety about sleep
• Misattribution of daytime problems to insomnia

Relaxation Techniques:

• Progressive muscle relaxation
• Diaphragmatic breathing (4-7-8 technique: inhale 4 seconds, hold 7, exhale 8)
• Guided imagery
• Mindfulness meditation

Hack #3: The "Cognitive Shuffle" technique: When lying awake, visualize random, non-emotional objects starting with each letter of a random word (e.g., BEDTIME: banana, elephant, doorknob...). This occupies the verbal-linguistic brain centers that generate worry, facilitating sleep onset without requiring extensive training.

Pharmacological Management

Medications should be used sparingly in acute insomnia, preferably for <2-4 weeks, and always in conjunction with behavioral strategies.

FDA-Approved Hypnotics:

Benzodiazepine Receptor Agonists (BzRAs):

• Zolpidem: 5-10 mg (5 mg for women, elderly); onset 30 minutes, half-life 2.5 hours (sleep onset insomnia)
• Eszopiclone: 1-3 mg; onset 30 minutes, half-life 6 hours (sleep maintenance)
• Zaleplon: 5-10 mg; onset 20 minutes, half-life 1 hour (middle-of-night dosing possible if ≥4 hours before wake time)

Side effects include residual sedation, dizziness, complex sleep behaviors (rare), and potential for dependence with prolonged use. Contraindications include severe respiratory disease, sleep apnea, and severe hepatic impairment.

Dual Orexin Receptor Antagonists (DORAs):

• Suvorexant: 10-20 mg; blocks wake-promoting orexin signaling
• Lemborexant: 5-10 mg; newer agent with similar mechanism
• Daridorexant: 25-50 mg; most recently approved

DORAs offer an alternative mechanism without GABA modulation, potentially lower abuse liability, and may be particularly effective for sleep maintenance difficulties.

Melatonin Receptor Agonists:

• Ramelteon: 8 mg; selective for MT1/MT2 receptors, useful for sleep onset, no controlled substance scheduling, minimal next-day effects

Pearl #4: Match medication pharmacokinetics to insomnia phenotype: sleep onset problems benefit from short half-life agents (zaleplon, zolpidem immediate-release); sleep maintenance problems benefit from longer-acting agents (eszopiclone, zolpidem extended-release, DORAs).

Off-Label Medications:

Low-dose sedating antidepressants:

• Doxepin 3-6 mg: FDA-approved at these doses for insomnia; H1 antagonism
• Trazodone 25-100 mg: widely used off-label; mixed evidence; watch for priapism (rare), orthostasis
• Mirtazapine 7.5-15 mg: sedating at low doses via H1 antagonism

Antihistamines:

• Diphenhydramine 25-50 mg, doxylamine: OTC availability but significant anticholinergic effects, tolerance develops rapidly, not recommended for routine use, particularly problematic in elderly

Oyster #2: Benzodiazepines (e.g., temazepam, triazolam) are rarely appropriate for acute insomnia in modern practice. Compared to newer agents, they have greater risks of cognitive impairment, falls, respiratory depression, abuse potential, and withdrawal. Reserve for exceptional circumstances only.

Oyster #3: Avoid combining sedative-hypnotics with opioids due to compounded respiratory depression risk. The FDA issued black box warnings for this combination in 2016.

Medications to Avoid or Use Cautiously:

• Antipsychotics (quetiapine): metabolic risks far outweigh benefits
• Long-acting benzodiazepines: excessive daytime sedation, falls, cognitive impairment
• Barbiturates: obsolete, dangerous
• Herbal supplements (valerian, kava): inconsistent evidence, potential hepatotoxicity (kava)

Special Populations

Elderly Patients: Increased sensitivity to sedative-hypnotics, higher fall risk, often have comorbid sleep-disordered breathing. Prefer behavioral interventions; if medication necessary, use lowest doses (zolpidem 5 mg, ramelteon 8 mg, or doxepin 3 mg). The Beers Criteria recommend avoiding benzodiazepines and "Z-drugs" in elderly when possible.

Pregnant Women: Avoid pharmacotherapy when possible. CBT-I is safe and effective. If necessary, occasional use of antihistamines may be considered, though evidence is limited. Benzodiazepines cross the placenta and are generally avoided.

Shift Workers: Focus on optimizing the sleep environment (blackout curtains), strategic caffeine use (not within 6 hours of sleep period), and potentially melatonin 2-3 mg before daytime sleep period.

Hack #4: For patients requiring middle-of-the-night dosing (awakening with >4 hours until desired wake time), zaleplon 5-10 mg can be used due to its ultra-short half-life, minimizing next-day sedation.

Prevention of Chronic Insomnia

The most critical aspect of acute insomnia management is preventing chronification. Key strategies include:

1. Early Intervention: Address insomnia within the first few weeks rather than waiting for chronicity
2. Limit Medication Duration: Time-limit hypnotic prescriptions to 2-4 weeks
3. Implement Behavioral Strategies Early: Don't rely solely on medications
4. Address Perpetuating Factors: Identify and modify maladaptive sleep behaviors
5. Treat Underlying Conditions: Pain, depression, anxiety, medical illness
6. Follow-up: Schedule reassessment within 2-4 weeks

Pearl #5: The best predictor of chronic insomnia is extended time in bed while awake. Aggressive sleep restriction in acute insomnia can interrupt the pathway to chronicity by preventing this maladaptive pattern from becoming entrenched.

When to Refer

Consider sleep medicine referral when:

• Symptoms persist beyond 3 months despite appropriate treatment
• Suspicion for sleep-disordered breathing, narcolepsy, RLS, or parasomnias
• Treatment-refractory insomnia
• Complex comorbidities requiring specialized management
• Need for polysomnography to rule out other sleep disorders

Conclusion

Acute insomnia represents a common yet consequential condition in internal medicine practice. A systematic approach emphasizing behavioral interventions, with judicious short-term pharmacotherapy when necessary, can effectively resolve symptoms and prevent progression to chronic insomnia. Internists should maintain a low threshold for addressing sleep complaints, as early intervention dramatically improves outcomes. As research continues to elucidate the bidirectional relationships between sleep and metabolic, cardiovascular, and psychiatric health, optimal insomnia management becomes increasingly recognized as a cornerstone of comprehensive internal medicine care.

Key References

1. American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd ed. Darien, IL: American Academy of Sleep Medicine, 2014.

2. Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(2):307-349.

3. Qaseem A, Kansagara D, Forciea MA, et al. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016;165(2):125-133.

4. Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675-700.

5. Spielman AJ, Caruso LS, Glovinsky PB. A behavioral perspective on insomnia treatment. Psychiatr Clin North Am. 1987;10(4):541-553.

6. Ellis JG, Perlis ML, Bastien CH, et al. The Natural History of Insomnia: Acute Insomnia and First-Onset Depression. Sleep. 2014;37(1):97-106.

7. Morin CM, Drake CL, Harvey AG, et al. Insomnia disorder. Nat Rev Dis Primers. 2015;1:15026.

8. Buysse DJ. Insomnia. JAMA. 2013;309(7):706-716.

---

Word Count: 2,000

Disclosure: No conflicts of interest to declare.